Prognostic and predictive markers in pancreatic adenocarcinoma (original) (raw)
Looking to the future: biomarkers in the management of pancreatic adenocarcinoma
Karen Mulder
International journal of molecular sciences, 2011
View PDFchevron_right
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer
Olga Ludkovski
Cancer, 2010
View PDFchevron_right
Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine
stephane cattan
In Vivo, 2017
View PDFchevron_right
Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel
Henrik Green
View PDFchevron_right
State of the art biological therapies in pancreatic cancer
Riccardo Casadei
World journal of gastrointestinal oncology, 2016
View PDFchevron_right
Identification of prognostic and predictive markers in pancreatic adenocarcinoma. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011
Suzanne Russo
Jop Journal of the Pancreas, 2011
View PDFchevron_right
Molecular prognostic factors in patients with pancreatic cancer
Daniele Santini
Expert Opinion on Therapeutic Targets, 2007
View PDFchevron_right
Individualizing therapy for pancreatic cancer
Neil Merrett
Journal of Gastroenterology and Hepatology, 2008
View PDFchevron_right
Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer
Anna M. Czarnecka
Oncology Letters, 2015
View PDFchevron_right
Pancreatic Cancer Cell Genetics and Signaling Response to Treatment Correlate with Efficacy of Gemcitabine-Based Molecular Targeting Strategies
Jesus Matos
Journal of Gastrointestinal Surgery, 2008
View PDFchevron_right
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
David Campos
Journal of Clinical Oncology, 2007
View PDFchevron_right
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research
JinSoo Kim
Investigational new drugs, 2011
View PDFchevron_right
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
Giovanni Brandi
Oncology Reports, 2010
View PDFchevron_right
Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer
Andrew Lowy
Clinical Cancer Research, 2013
View PDFchevron_right
Novel Biomarkers in Pancreatic Cancer
Radu Albulescu
Pancreatic Cancer - Clinical Management, 2012
View PDFchevron_right
Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma
stephane garcia
The American Journal of Pathology, 2015
View PDFchevron_right
Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study
Salomon Stemmer
BioMed Research International, 2015
View PDFchevron_right
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
C. Hillenbach, I. Davidenko
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2014
View PDFchevron_right
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Arndt Weinmann
Journal of Clinical Oncology, 2017
View PDFchevron_right
A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Marion Hartley
Journal of Pancreatic Cancer, 2019
View PDFchevron_right
Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients
Yoichi Hiasa
BMC Gastroenterology, 2013
View PDFchevron_right
Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy
Jaswinder Samra
Frontiers in Oncology, 2020
View PDFchevron_right
A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics
yalda zolghadri
Disease Models & Mechanisms, 2015
View PDFchevron_right
Phase II study evaluating the association of gemcitabine, trastuzumab, and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)
Eric Assenat
Journal of Clinical Oncology, 2015
View PDFchevron_right
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
Jeffrey Clark
Journal of Clinical Oncology, 2007
View PDFchevron_right
Pancreatic cancer: from molecular pathogenesis to targeted therapy
KOSTAS SYRIGOS
Cancer and Metastasis Reviews, 2008
View PDFchevron_right
Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation
Konstantine Kalogeras
Cancer Investigation, 2008
View PDFchevron_right